aromasin - search results

aromasin

pfizer pfe pharmaceuticals israel ltd - exemestane - coated tablets - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

aromasin exemestane 25mg tablet blister pack

pfizer australia pty ltd - exemestane, quantity: 25 mg - tablet, sugar coated - excipient ingredients: silicon dioxide; crospovidone; hypromellose; magnesium carbonate hydrate; mannitol; microcrystalline cellulose; methyl hydroxybenzoate; macrogol 6000; polysorbate 80; polyvinyl alcohol; sodium starch glycollate; sucrose; titanium dioxide; cetyl esters wax; purified talc; carnauba wax; shellac; iron oxide black; magnesium stearate; purified water; dimeticone 100; dimeticonol; benzoic acid; sorbic acid - aromasin is indicated for the sequential adjuvant treatment of estrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy.,aromasin is indicated for the treatment of estrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-estrogen therapy.

United States - English - NLM (National Library of Medicine)

aromasin- exemestane tablet

pharmacia & upjohn company llc - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - aromasin is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)]. aromasin is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2)]. aromasin is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, aromasin can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abortions, embryo-fetal toxicit

United States - English - NLM (National Library of Medicine)

aromasin- exemestane tablet

physicians total care, inc. - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - aromasin is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy. aromasin is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. aromasin tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

aromasin

pfizer australia pty ltd - exemestane -